Sinovac’s trivalent influenza vaccine has been expanded to cover all age groups, including those 6 months and older.
October 30, 2025
Source: drugdu
89
According to Sinovac BiotechNews: On October 23, 2025, Beijing Sinovac Biotech Co., Ltd. produced a trivalent influenza vaccine.The National Medical Products Administration (NMPA) has approved the expanded age range for the Sinovac Biotech vaccine Anlelaifu® (0.5ml/dose), increasing the target population to include individuals aged 6-35 months and expanding the applicable population to all individuals aged 6 months and older. This month, Sinovac's quadrivalent influenza vaccine (0.5ml/dose) and trivalent influenza vaccine (0.5ml/dose) have also received approval for expanded age ranges, meaning the company's seasonal influenza vaccines now offer a unified dosage form for individuals aged 6 months and older.
Source: https://finance.eastmoney.com/a/202510303549825713.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
